Development of a tumor-specific photoactivatable doxorubicin prodrug

Photochemistry and Photobiology

Volumn 89, Issue 5, 2013, Pages 1009-1010

  Girotti, Albert W ^a   Minotti, Giorgio ^b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

DOXORUBICIN; DRUG DERIVATIVE; PHOTOSENSITIZING AGENT; PRODRUG;

ANIMAL; ARTICLE; FEMALE; HUMAN; LUNG TUMOR; METABOLISM; PHOTOCHEMOTHERAPY;

ANIMALS; DOXORUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PRODRUGS;

EID: 84884136206     PISSN: 00318655     EISSN: 17511097     Source Type: Journal    
DOI: 10.1111/php.12151     Document Type: Article

References (22)

1. Gewirtz, D. A., (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 57, 727-741.
2. Minotti, G., P. Menna, E. Salvatorelli, G. Cairo, and, L. Gianni, (2004) Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229.
3. Murphy, G. P., W. Lawrence Jr, and, R. E. Lenhard, (eds.) (1995) American Cancer Society Textbook of Clinical Oncology, 2nd edn. American Cancer Society, Atlanta, GA.
4. Wiernick, P. H., and, J. P. Dutcher, (1992) Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 6 (Suppl 1), 67-69.
5. Deffie, A. M., J. K. Batra, and, G. J. Goldenberg, (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res. 49, 58-62.
6. Calendi, E., A. Di Marco, M. Reggiani, B. Scarpinato, and, L. Valentini, (1965) On physico-chemical interactions between daunomycin and nucleic acids. Biochim. Biophys. Acta 103, 25-49.
7. Shapiro, C. L., and, A. Recht, (2001) Side effects of adjuvant treatment of breast cancer. N. Engl. J. Med. 344, 1997-2008.
8. Olson, R. D., and, P. S. Mushlin, (1990) Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses. FASEB J. 4, 3076-3086.
9. Pawan, N. I., and, K. Singal, (1998) Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905.
10. Davies, K. J. A., and, J. H. Doroshow, (1986) Redox cycling of anthracyclines by cardiac mitochondria: I. anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 261, 3060-3067.
11. Berthiaume, J. M., and, K. B. Wallace, (2007) Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol. Toxicol. 23, 15-25.
12. Davies, K. J. A., and, J. H. Doroshow, (1986) Redox cycling of anthracyclines by cardiac mitochondria: II. formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 261, 3068-3074.
13. Zhang, S., X. Liu, T. Bawa-Khalfe, L. S. Lu, Y. L. Lyu, L. F. Liu, and, E. T. Yeh, (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642.
14. Aluise, C. D., R. Sultana, J. Tangpong, M. Vore, D. St. Clair, J. A. Moscow, and, D. A. Butterfield, (2010) Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: Role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv. Exp. Med. Biol. 678, 147-156.
15. Raffa, R. B., (2010) A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog'). J. Clin. Pharm. Ther. 36, 257-259.
16. Ibsen, S., E. Zahavy, W. Wrosidlo, T. Hayashi, J. Norton, Y. Su, S. Adams, and, S. Esener, (2013) Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue. Photochem. Photobiol. 89, 698-708.
17. Ibsen, S., E. Zahavy, W. Wrosidlo, M. Berns, M. Chan, and, S. Esener, (2010) A novel doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm. Res. 27, 1848-1860.
18. Amit, B., U. Zehavi, and, A. Patchornik, (1974) Photosensitive protecting groups of amino sugars and their use in glycoside synthesis: 2-nitrobenzyloxycarbonylamino and 6-nitroveratryloxycarbonylamino derivatives. J. Org. Chem. 39, 192-196.
19. Gabizon, A. A., (2001) Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19, 424-436.
20. Lutz, M. N., F. Tietze, T. Mollers, R. Fischer, K.-H. Glusenhamp, M. F. Rajewsky, and, E. Jadhe, (1989) Proton-mediated liberation of aldophosphamide from a non-toxic prodrug: A strategy for tumor-selective activation of cytocidal drugs. Cancer Res. 49, 4179-4184.
21. Wilson, W. R., and, J. M. Brown, (2004) Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447.
22. Breistol, H. R. H. K., D. P. Berger, S. P. Langdon, H. H. Fiebig, and, O. Fodstad, (1998) The antitu;mor activity of the prodrug N-1-leucyl-doxorubicin and its parent compound doxorubicin in human tumor xenografts. Eur. J. Cancer 34, 1602-1606.